EHA 2020 | Advances in risk-stratification in pediatric ALL

Name: Advances in risk-stratification in pediatric ALL
Uploaded: 2020-06-22T00:00:00Z
Duration: 4 min 37 s
Description: Anthony Moorman, PhD, Newcastle University, Newcastle, UK touches on advances in risk-stratification in pediatric acute lymphoblastic leukemia (ALL) including the significance of measurable residual disease (MRD) and identification of genomic variants. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Anthony Moorman • 22 Jun 2020

EHA 2020

Acute Lymphoblastic Leukemia Leukemia Imatinib

Anthony Moorman, PhD, Newcastle University, Newcastle, UK touches on advances in risk-stratification in pediatric acute lymphoblastic leukemia (ALL) including the significance of measurable residual disease (MRD) and identification of genomic variants. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).